Prevalence of virulence genes among bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa

Brazilian Journal of Microbiology

Volumn 41, Issue 3, 2010, Pages 588-595

  Mitov, Ivan ^a   Strateva, Tanya ^a   Markova, Boyka ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Cystic fibrosis isolates; Non cystic fibrosis isolates; Polymerase chain reaction; Pseudomonas aeruginosa; Virulence genes

Indexed keywords

PSEUDOMONAS AERUGINOSA;

EID: 77954303046     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822010000300008     Document Type: Article

References (24)

1. Allewelt, M.; Coleman, F.T.; Grout, M.; Priebe, G.P.; Pier, G.B. (2000). Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect. Immun. 68 (7), 3998-4004.
2. Alonso, A.; Campanario, E.; Martinez, J.L. (1999). Emergence of multidrugresistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145 (10), 2857-2862.
3. Canton, R.; Cobos, N.; de Gracia J.; Baquero, F.; Honorato, J.; Gartner, S.; Alvarez, A.; Salcedo, A.; Oliver, A.; Garcia-Quetglas, E. on behalf of the Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient. (2005). Antimicrobial therapy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 11 (9), 690-703.
4. CFF. (1994). Microbiology and infectious disease in cystic fibrosis. Consensus Conference. Concepts in Care Vol. 5, section 1, Bethesda MD: Cystic Fibrosis Foundation.
5. th informational supplement, M100-S17. Wayne PA: Clinical and Laboratory Standards Institute.
6. Dacheux, D.; Toussaint, B.; Richard, M.; Brochier, G.; Croize, J.; Attree, I. (2000). Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect. Immun. 68 (5), 2916-2924.
7. Di Martino, P.; Gagniere, H.; Berry, H.; Bret, L. (2002). Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patients. Microbes Infect. 4 (6), 613-620.
8. Feltman, H.; Schulert, G.; Khan, S.; Jain, M.; Peterson, L.; Hauser, A.R. (2001). Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147 (10), 2659-2669.
9. Finnan, S.; Morrissey, J.P.; O'Gara, F.; Boyd, E.F. (2004). Genome diversity of Pseudomonas aeruginosa isolates from cystic fibrosis patients and the hospital environment. J. Clin. Microbiol. 42 (12), 5783-5792.
10. Garey, K.W.; Vo, Q.P.; Larocco, M.T.; Gentry, L.O.; Tam, V.H. (2008). Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J. Chemother. 20 (6), 714-720.
11. Hauser, A.R.; Cobb, E.; Bodi, M.; Mariscal, D.; Valles, J.; Engel, J.N.; Rello, J. (2002). Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30 (3), 521-528.
12. Hoyle, B.D.; Costeron, W.J. (1991). Bacterial resistance to antibiotics: the role of biofilms. Prog. Drug Res. 37, 91-105.
13. Jones, R.N. (2001). Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119 (2 Suppl.), 397S-404S.
14. Karlowsky, J.A.; Draghi, D.C.; Jones, M.E.; Thornsberry, C.; Friedland, I.R.; Sahm, D.F. (2003). Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001. Antimicrob. Agents Chemother. 47 (5), 1681-1688.
15. Lanotte, P.; Watt, S.; Mereghetti, L.; Dartiguelongue, N.; Rastegar-Lari, A.; Goudeau, A.; Quentin, R. (2004). Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J. Med. Microbiol. 53 (1), 73-81.
16. Leprat, R.; Michel-Briand, Y. (1980). Extracellular neuraminidase production by a strain of Pseudomonas aeruginosa isolated from cystic fibrosis. Ann. Microbiol. 131B (3), 209-222.
17. Mah, T.F.; Pitts, B.; Pellock, B.; Walker, G.C.; Stewart, P.S.; O'Toole G.A. (2003). A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426 (6964), 306-310.
18. Schulert, G.S.; Feltman, H.; Rabin, S.D.; Martin, C.G.; Battle, S.E.; Rello, J.; Hauser A.R. (2003). Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J. Infect. Dis. 188 (11), 1695-1706.
19. Stewart, P.C. (2002). Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292 (2), 107-113.
20. Strateva, T. (2008). Microbiological and molecular-genetic investigations on resistance mechanisms and virulence factors in clinical strains of Pseudomonas aeruginosa. Sofia, Bulgaria, 210 p. (Ph.D. Dissertation, Medical University of Sofia, Bulgaria).
21. Strateva, T.; Petrova, G.; Perenovska, P.; Mitov, I. (2009). Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution. J. Med. Microbiol. 58 (5), 690-692.
22. Van Delden, C.; Iglewski, B.H. (1998). Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg. Infect. Dis. 4 (4), 551-560.
23. Whiteley, M.; Bangera, M.G.; Bumgarner, R.E.; Parsek, M.R.; Teitzel, G.M.; Lory, S.; Greenberg, E.P. (2001). Gene expression in Pseudomonas aeruginosa biofilms. Nature 413 (6858), 860-864.
24. Zaborina, O.; Kohler, J.E.; Wang, Y.; Bethel, C.; Shevchenko, O.; Wu, L.; Turner, J.R.; Alverdy, J.C. (2006). Identification of multi-drug resistant Pseudomonas aeruginosa clinical isolates that are highly disruptive to the intestinal epithelial barrier. Ann. Clin. Microbiol. Antimicrob. 5, 14.